Last reviewed · How we verify
NCT05214404
Effect and Mechanism of Dopamine on Ulcerative Colitis
trial testing Patients diagnosed with ulcerative colitis in Dopamine Dysregulation Syndrome in 60 participants. Completed in 20 September 2022.
30 August 2022
Quick facts
| Lead sponsor | Affiliated Hospital to Academy of Military Medical Sciences |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 16 February 2022 |
| Primary completion | 30 August 2022 |
| Estimated completion | 20 September 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- Patients diagnosed with ulcerative colitis
Conditions studied
- Dopamine Dysregulation Syndrome — all drugs for Dopamine Dysregulation Syndrome →
- Ulcerative Colitis — all drugs for Ulcerative Colitis →
Sponsor
Affiliated Hospital to Academy of Military Medical Sciences
Who can join
18 and older, any sex, with Dopamine Dysregulation Syndrome or Ulcerative Colitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Increased evidence suggests that dopamine acts as an important regulator of immune function. A substantial amount of dopamine exists in the gastrointestinal tract, especially in colonic lumen. Decreased dopamine level has been reported in the colonic mucosa of ulcerative colitis patients. Therefore, the investigators suppose that colonic dopamine could involve in the ulcerative colitis and play an important role. This study aims to explore the role of dopamine in ulcerative colitis and underlying mechanism, which will provide a rationale for diagnosis and treatment of the ulcerative colitis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05214404
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Affiliated Hospital to Academy of Military Medical Sciences trials
Trials by the same sponsor.
- NCT06986434 — CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differenti · EARLY_PHASE1 · not yet recruiting
- NCT07416682 — CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms · EARLY_PHASE1 · not yet recruiting
- NCT06834529 — CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma · Phase 1, PHASE2 · recruiting
- NCT06152263 — LCI in Chronic Atrophic Gastritis and Early Gastric Cancer · unknown
- NCT05645601 — CAR-NK Targeted CD19 for r/r B-cell Malignancies · Phase 1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05214404 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Affiliated Hospital to Academy of Military Medical Sciences
- Last refreshed: 26 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05214404.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing